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Abstract
Angiogenesis is a critical process in the progression of advanced renal cell carcinoma. Agents targeting angiogenesis
have played a primary role in the treatment of metastatic renal cell carcinoma. However, resistance to anti-angiogenesis
therapy almost always occurs, and major progress has been made in understanding its underlying molecular
mechanism. Axitinib and everolimus have been used extensively in patients whom have had disease progression
after prior anti-angiogenesis therapy. Recently, several new agents have been shown to improve overall survival in
comparison with everolimus. This review provides an in-depth summary of drugs employable in the clinical setting,
the rationale to their use, and the studies conducted leading to their approval for use and provides perspective on
the paradigm shift in the treatment of renal cell carcinoma. Highlighted are the newly approved agents cabozantinib,
nivolumab, and lenvatinib for advanced renal cell carcinoma patients treated with prior anti-angiogenesis therapy.
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Background
Each year, over 320,000 individuals will be diagnosed with
renal cell carcinoma (RCC) accounting for an annual
death toll of over 140,000 people. The incidence of RCC
has steadily risen over the past 10 years and accounts for
2–3% of all adult malignancies [1]. Upon the diagnosis of
RCC, curative surgery is an option for those with early
stage localized tumors. However, localized disease may
undergo early hematogenous dissemination leading to
metastasis. Sites of early metastases include the lungs,
lymph nodes, liver, bone, and brain. RCC can also
metastasize to the adrenal glands, the contralateral kidney,
although less commonly [2]. Individuals with advanced
disease face high rates of morbidity and mortality with a
median 5-year survival rate of 53% for stage III disease
and 8% for metastatic disease [3, 4]. However, death rates
from RCC have remained stable or decreased in most
countries with advanced healthcare [5]. This steady de-
cline can be attributed to the advent of new biological
agents rapidly developed over the past few years that are
readily employable in the clinical setting.
RCC is a heterogeneous disease and is subcategorized
based on histological and cytogenetic signatures, with
80% characterized as clear cell renal cell carcinoma
(ccRCC) and 20% as non-clear cell carcinoma (nccRCC)
[6]. Both types can occur either sporadically or due to a
hereditary predisposition. However, both forms are asso-
ciated with gene mutations to the short arm of chromo-
some 3 and specifically to the VHL tumor suppressor
gene [7, 8]. In the natural setting, the VHL gene encodes
the substrate recognition module of a ubiquitin ligase
that targets hypoxia-inducible factor (HIF) for destruc-
tion in the presence of oxygen. However,VHL is mutated
or methylated in up to 90% of patients with ccRCC [9].
When the VHL gene is mutated, its tumor suppressor
function is lost and HIF accumulates to high levels, lead-
ing to the activation of multiple genes including vascular
endothelial growth factor (VEGF) and platelet-derived
growth factor (PDGF). Ultimately, this cascade of events
culminates in unregulated cell growth, uncontrolled
angiogenesis, and increased tumor-cell invasion.
Elucidation of this underlying pathway has led to the
development of a number of target-based therapies for
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patients with advanced RCC. Prior to the advances in thera-
peutics seen over the last decade, the mainstay of treatment
for metastatic disease was cytokine-based treatment with
high dose interleukin-2 (IL-2) and interferon-alpha (IFN-α)
after their FDA approval in the 1990s [10]. Although this
therapy regimen produced objective responses, there were
significant toxicities, treatment benefit was only seen in 5–
15% of patients, and outcome for the majority of patients
was poor [11, 12]. Since 2004, the advances in target-based
therapy and immunotherapy modalities have created a
paradigm shift in the treatment of RCC. These agents have
had a remarkable effect on patient outcomes with increased
progression-free survival rates; however, virtually all pa-
tients eventually develop the progression of disease [7]. The
high likelihood of disease progression remains a challenge
due to therapeutic resistance. Refractory disease is currently
being managed with sequentially changing therapy, but
morbidity and mortality remain high. Herein, we review the
most up-to-date practices and emerging therapies for the
treatment of refractory RCC after anti-angiogenesis therapy
and focus on newly approved agents including cabozanti-
nib, nivolumab, and lenvatinib.
The primary role of anti-angiogenesis in first-line
therapy for mRCC
The armamentarium of agents approved for the first-line
treatment of metastatic RCC (mRCC) has rapidly devel-
oped over the years and now includes the small-molecule
VEGF tyrosine kinase inhibitor (TKI)-sunitinib and pazopa-
nib, a monoclonal antibody targeting VEGF-bevacizumab
in combination with interferon, and an mammalian target
of rapamycin (mTOR) inhibitor-temsirolimus, as well as
high dose IL-2. In the recent past, the approach to the
treatment of patients with mRCC entailed sequential em-
ployment of agents targeting VEGF or mTOR pathways.
Agents with anti-angiogenesis properties have become the
mainstay of initial therapy for advanced RCC due to their
preferable efficacy and toxicity profile. The current level 1
recommendation from the National Comprehensive Cancer
Network (NCCN) and the European Association or
Urology is the use of oral, multi-target, tyrosine kinase
inhibitors (TKIs)—specifically sunitinib and pazopanib—in
the first-line setting [13, 14].
VEGF-targeted tyrosine kinase inhibitors
Sunitinib is an orally administered multi-target TKI of
VEGFR, PDGFR, and c-Kit and is generally well tolerated.
Originally, sunitinib demonstrated a progression-free sur-
vival (PFS) of 8.3 months in patients who progressed on
one line of cytokine-based therapy. This led to a follow-up
study on its use as a first-line agent [15]. A pivotal phase III
clinical trial involving 750 treatment-naïve patients was
conducted to compare sunitinib to IFN-α as first-line treat-
ment for mRCC. The study met its primary endpoint, PFS,
and sunitinib demonstrated a superior PFS of 11 months
compared to 5 months with IFN-α. Sunitinib also proved
superior in overall survival (OS) with 26.4 months as com-
pared to 21.8 months for IFN-α [15]. The side-effect profile
has been studied thoroughly, and common adverse effects
include hypertension (12%), fatigue (11%), diarrhea (9%),
and hand-foot syndrome (9%) [16].
In light of its favorable safety and tolerability profile, a
second TKI, pazopanib, was studied in the mRCC popu-
lation [17]. A phase III, double-blind, placebo-controlled
study was designed to evaluate pazopanib in 435
treatment-naïve or cytokine-pretreated patients. Pazopa-
nib was shown to prolong mPFS compared to placebo
(11.1 vs. 2.8 months) and to cytokine-pretreatment (7.4
vs. 4.2 months). Sternberg et al. reported a median OS
of 22.9 months with pazopanib and 20.5 months with
placebo [18]. Common pazopanib toxicities during this
trial included diarrhea (52%), hypertension (40%), hair
color changes (38%), and nausea (26%) [17].
In order to select the optimal first-line therapy, head-to-
head comparison studies were performed for these two
TKIs. In 2013, Motzer et al. presented the COMPARZ trial,
a global, phase III, randomized, open-label trial comparing
sunitinib and pazopanib as first-line agents. Both agents
performed similarly, and the mPFS of pazopanib was
10.5 months compared to 10.2 months for sunitinib. OS
analysis resulted in 28.4 and 29.3 months for pazopanib
and sunitinib, respectively. Overall clinical efficacy was not
discernable between the two agents, and pazopanib was
concluded to be non-inferior to sunitinib [19]. In addition
to the COMPARZ trial, the PISCES study investigated
patient-reported outcomes with regard to pazopanib and
sunitinib tolerability and patient preference. Stratification of
data from this questionnaire-based study revealed a signifi-
cant number of patients preferred pazopanib over sunitinib.
There was a 49% reported difference in preference between
the two agents [20]. Interestingly, both agents have
uniquely different side-effect profiles despite similar target
pathways and mechanisms of action. Pazopanib has a lower
incidence of hand-foot syndrome, fatigue, and myelosu-
pression but notable for more frequent hepatic injury. Such
a discernable difference in toxicities has been used as a tool
to tailor therapy for mRCC patients based on their respect-
ive comorbidities [21].
Other TKIs include sorafenib, axitinib, and cabozantinib
which were also tested in the first-line setting. Sorafenib
was introduced as the first targeted therapy for mRCC in
2004 [22]. An oral, multi-kinase inhibitor of tumor-cell
proliferation and tumor angiogenesis, sorafenib, is currently
indicated for the treatment of renal, liver, and thyroid
cancers. A phase III study, presented as the TARGET trial,
enlisted 903 mRCC patients with disease refractory to high
dose IL-2 and IFN-α and stratified patients to a placebo or
sorafenib treatment group. Sorafenib outperformed placebo
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in mPFS 5.5 to 2.8 months, respectively [23]. Originally, no
significance was found in OS from the study data; however,
further analysis censoring placebo patients with crossover
demonstrated a survival advantage for sorafenib-treated pa-
tients. Moreover, the TARGET trial also provided data sug-
gesting VEGF levels are prognostic for mPFS and OS in
mRCC [24]. It must be noted, however, that sorafenib did
not improve PFS when compared to IFN-α-2a in the first-
line setting [25].
Axitinib, initially approved in the second-line setting,
was also studied as a first-line agent in comparison with
sorafenib in a randomized, open-label, phase III clinical
trial. Although axitinib demonstrated clinical activity
with an acceptable safety profile, there was no significant
difference in mPFS in patients with treatment-naïve
mRCC compared with those treated with sorafenib in
the first-line setting [26].
Most recently, the European Society for Medical On-
cology announced the results of a phase II multicenter
study comparing cabozantinib and sunitinib in the first-
line setting. One hundred fifty-seven patients were ran-
domized to receive either agent, and the cabozantinib
treatment group showed a 31% reduction in the median
rate of progression or death compared to those treated
with sunitinib [27]. Although the results are promising,
more expansive studies will be needed including phase
III studies to solidify the role of cabozantinib in patients
with untreated mRCC.
Monoclonal antibody targeting VEGF
Bevacizumab is a humanized recombinant monoclonal
antibody against VEGF-A [28]. It was originally evalu-
ated in a randomized phase II trial showing increased
time to disease progression in patients who failed
high-dose IL-2 [29]. Such promising data culminated
in the AVOREN trial, a phase III, randomized, double-
blinded study of 641 patients treated with bevacizu-
mab plus IFN-α or placebo with IFN-α. Study results
include bevacizumab benefit with mPFS (10.2 vs.
5.4 months), RR (30.6 vs. 12.4%), and a trend towards
improved survival [30, 31]. A similar trial studying the
viability of bevacizumab in the first-line setting (the
CALBG trial) randomized patients to receive bevacizu-
mab with IFN-α or IFN-α alone. In concordance with
the AVOREN trial, the CALBG study showed that the
patients in the bevacizumab arm had a greater mPFS
and RR. These data propelled bevacizumab as a viable
first-line agent alongside sunitinib and pazopanib ther-
apies [32]. Bevacizumab has been studied in combin-
ation with sunitinib, sorafenib, or temsirolimus, and all
encountered significant dose-limiting toxicities [30–33].
Currently, bevacizumab in combination with interferon
has a category 1 NCCN recommendation for mRCC.
mTOR inhibitors
A serine/threonine kinase and member of the PI3K family,
mammalian target of rapamycin (mTOR), is implicated in
the activation of a number of growth factors and signaling
cascades, therefore having implications in tumorigenesis
and angiogenesis [33–35]. Interestingly, the role of mTOR
signaling in solid cancers was primarily investigated in the
RCC model with the ultimate development of targeted
agents for systemic therapy in mRCC patients [36, 37].
Over the past few years, experts have supported the grow-
ing body of evidence that there is a greater efficacy of
VEGFR inhibitors compared to mTOR inhibitors in pa-
tients with mRCC [38]. Notwithstanding, temsirolimus
and everolimus have had principal roles in mRCC in both
the first-line and refractory setting.
Temsirolimus is the only mTOR inhibitor approved for
the first-line treatment of mRCC with poor prognosis. In
the phase III Global ARCC trial, temsirolimus was studied
for first-line use in 626 previously untreated patients with
mRCC with poor prognosis features based on MSKCC
prognostic model. Participants were considered poor prog-
nosis if three of the following six criteria were met: LDH ≥
1.5 ×ULN, Ca++ of ≥10 mg/dL, diagnosis to treatment initi-
ation of <1 year, KPS 60–70%, ≥2 metastatic sites [39]. Of
note, this study was indiscriminant of histological subtype
and included both ccRCC and nccRCC subjects. ARCC
compared IFN-α or a combination of temsirolimus and
IFN-α. Temsirolimus monotherapy demonstrated a super-
ior OS of 10.9 months compared to either IFN-α
(7.3 months) or combination therapy (8.4 months). ARCC
also reported temsirolimus to have a superior mPFS of
3.8 months over IFN-α (1.9 months) [40]. Temsirolimus is
currently recommended by the NCCN for first-line use in
patients with mRCC with features of poor prognosis.
While temsirolimus has not been compared directly
with either sunitinib or pazopanib in the first-line setting
for patients with mRCC, the issue of optimal sequencing
between VEGF TKIs and mTOR inhibitors was ad-
dressed in the RECORD-3 trial using a different mTOR
inhibitor, everolimus. RECORD-3 was a phase II study
comparing the mPFS of treatment-naïve mRCC patients
treated with sequential first-line everolimus and second-
line sunitinib versus first-line sunitinib and second-line
everolimus. The use of everolimus followed by sunitinib
failed to demonstrate non-inferiority with regard to
mPFS. To this end, study outcomes did not support the
use of everolimus in first-line setting [41].
Paradigm shift in the treatment of mRCC after
anti-angiogenesis therapy
The primary challenge of mRCC is that complete response
to treatment with a single agent is rare. Disease progression
is expected and tumor resistance is an inevitable reality.
mRCC remains incurable in most instances, and
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mechanisms of tumor-cell resistance to conventional radio-
therapy and chemotherapy have been an active area of re-
search. Proposed mechanisms include overexpression of
multidrug resistance gene MDR-1, cell survival gene
clusterin, PKC-ζ, L2 cell adhesion molecule L1-CAM, P-
glycoprotein, various DNA repair proteins, the antia-
poptotic gene bcl-2, glutathione S-transferase, decreased
expression of DNA topoisomerase, loss of HIF-1α regula-
tion, accumulation of HIF-2α, and suppression of p53 [40,
42]. Targeting these resistance mechanisms is an area of on-
going studies and may play a role in future approaches to
the treatment of advanced RCC.
Prior to the approval of everolimus by FDA in 2009
for the second-line use in mRCC, there was no estab-
lished treatment option for patients who progressed on
first-line VEGF-directed therapy. Significant advance-
ment has been made since, and the second-line treat-
ment options now include TKIs—axitinib, cabozantinib,
and lenvatinib; an anti-PD1 monoclonal antibody, nivo-
lumab; and an mTOR inhibitor, everolimus. Sequential
treatments have emerged as a viable approach to con-
trolling drug resistance and overcoming resistance
mechanisms [43], while the optimal sequence of treat-
ment remains to be defined as few studies to date have
directly compared drug efficacy [44].
Everolimus
The oral agent mTOR inhibitor, everolimus, was the first
drug to be approved for second-line use in mRCC after
progression on first-line VEGF TKI treatment. In the
RECORD-1 trial, everolimus was compared to placebo in
410 mRCC patients whom had been previously treated for
at least 6 months with sunitinib, sorafenib, or both [45].
The study’s primary endpoint was mPFS, and everolimus
performed superiorly to placebo with a significant mPFS
difference of 4.0 to 1.9 months, respectively. A follow-up
trial, RECORD-4, prospectively followed mRCC patients on
everolimus after the progression of disease on either suniti-
nib, additional VEGF TKIs, or cytokine therapy [46] and
confirmed the mPFS benefit of everolimus. The role of
everolimus has been investigated beyond the second-line
setting and investigators proposed that mTOR inhibition
may have a role in untreated nccRCC. The ASPEN trial
was a multicenter, open-label, randomized phase II trial
designed to determine the mPFS of sunitinib and everoli-
mus in a subset of patients with histologically proven
nccRCC. Results favored sunitinib over everolimus (8.3 vs.
5.6 months) and reaffirmed the role of everolimus solely as
a second-line agent, irrespective of histological subtype [47].
Sorafenib and axitinib
The role of second-line sorafenib has been investigated
in the INTORSECT trial, which enrolled patients whom
had progressed after sunitinib therapy and randomized
them to receive either temsirolimus or sorafenib with a
primary endpoint of mPFS and secondary endpoints of
safety, ORR and OS. The study concluded there was no
difference in mPFS between the two agents; however, so-
rafenib demonstrated a superior OS of 16.6 months over
temsirolimus, 12.3 months. Both agents presented with
an acceptable safety profile, and the adverse effects were
consistent with the known toxicities of the drugs [48].
Axitinib is an oral, potent, small-molecule TKI that se-
lectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3 [49].
The role of axitinib in the second-line treatment of mRCC
has been investigated in the phase III AXIS trial, which
randomized 723 patients with mRCC whom had disease
progression after first-line systemic therapy [41]. First-line
therapy included sunitinib, cytokine therapy, bevacizumab
plus IFN-α, or temsirolimus. The trial met its primary
endpoint, mPFS, and axitinib was shown to offer a super-
ior mPFS of 6.7 months compared to sorafenib,
4.7 months. There was, however, no difference in the OS
between the axitinib-treated group and sorafenib-treated
group [50]. Common axitinib toxicities observed in the
study included diarrhea (55%), hypertension (40%), and fa-
tigue (39%).
Cabozantinib
The second-line agents everolimus and axitinib had
become the standard of care in refractory disease, but
the mPFS was only extended by a mere 3 to 5 months
after disease advancement on first-line therapy [41, 48].
Within the past year, two novel VEGFR TKIs, cabozanti-
nib and lenvatinib, have gained FDA approval for use in
advanced RCC.
Cabozantinib is an oral, small-molecule TKI-targeting
VEGFR that was originally approved for metastatic medul-
lary thyroid cancer. In addition to VEGFR, cabozantinib
targets receptor tyrosine kinases implicated in and relevant
to mRCC; RET, KIT, AXL, and FLT3 [51]. A landmark
study by Zhou et al. provided evidence that MET and AXL
are upregulated in chronic sunitinib use and play a role in
RCC tumor resistance to TKIs [52]. This data is in con-
cordance with previous studies which suggest poor progno-
sis when MET/AXL are highly expressed by RCC tumor
cells [53]. Cabozantinib was studied in the METEOR trial,
which was a randomized, open-label, phase III trial com-
paring cabozantinib with everolimus in 658 patients with
mRCC whom had advanced after TKI therapy. The study’s
primary endpoint was mPFS and secondary endpoints were
OS and ORR. The rate of disease progression with cabo-
zantinib was 42% lower than with everolimus. The ME-
TEOR trial met its primary endpoint, and cabozantinib
demonstrated a superior mPFS of 7.4 months compared to
3.8 months with everolimus. An OS advantage was ob-
served with cabozantinib (21.4 compared to 16.5 months),
and the ORR significantly favored cabozantinib to
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everolimus, 21 to 5% (p < 0.001) [38]. Cabozantinib was
observed to have a similar safety profile to drugs in its own
class (Table 1). The incidence of grade 3 and 4 adverse
effects was 68% with cabozantinib. The most common
events were hypertension (15%), diarrhea (11%), and fatigue
(9%). Dose reductions occurred in 60% of the study patients
stratified to cabozantinib treatment. A grade 5 adverse
event occurred in one patient [54].
The METEOR trial was published in November of 2016,
and by April 2016, the FDA had approved cabozantinib as
second-line treatment for advanced mRCC after anti-
angiogenesis therapy. As to the question of where cabozan-
tinib fits in the sequential treatment paradigm, its superior-
ity to everolimus leaves axitinib as a possible comparator
for a future study. Similar to the METEOR trial, the AXIS
trial investigated disease refractory to sunitinib. Subgroup
and post hoc analyses of the AXIS trial revealed that the pa-
tients whom had been treated with sunitinib and axitinib
sequentially had a mPFS of 4.8 months and an ORR of 11%
[41, 55]. Considering the 9.1-month mPFS and ORR of
22% observed in this study, cabozantinib could be a marked
advancement in the treatment of mRCC. Moreover, the
success of cabozantinib serves as a proof-of-principle that
the targets (MET and AXL) that were not affected by previ-
ous drugs have an in vivo role in mRCC disease.
Lenvatinib in combination with everolimus
One month after the FDA announcement of approval of
cabozantinib for mRCC, lenvatinib was approved for the
treatment of patients with advanced mRCC in combination
with everolimus following disease resistance to TKIs. Len-
vatinib is an oral, multi-target TKI of VEGFR1-3, FGFR1-4,
PDGFRα, RET, and KIT [56]. First established as a therapy
for differentiated thyroid cancer, lenvatinib has had a favor-
able antitumor profile with acceptable toxicities in a multi-
tude of solid tumors in both phase I and II trials [57, 58].
The mechanism by which tumors develop VEGF resistance
and develop compensatory angiogenesis pathways provides
the rationale for studies on drugs with multiple targets [59].
Prior in vivo studies using mouse xenografts of human
RCC showed a reduction in tumor volume with a lenvati-
nib and everolimus combination [60]. Further, in vitro
binding studies reveal a highly specific binding site to the
receptor kinase domain, suggesting possible limited toxic
effects [61]. To this end, lenvatinib had been identified as a
candidate for clinical studies in patients with advanced
mRCC refractory to first-line agents.
The role of lenvatinib in the treatment of mRCC has
been studied in a randomized, phase II, open-label, mul-
ticenter trial, which enrolled 153 patients with mRCC
that progressed on first-line VEGF-directed therapy [62].







Any grade (%) Grade 3/4 (%) Any grade (%) Grade 3/4 (%) Any grade (%) Grade 3/4 (%)
Diarrhea 85 11 13 1 72 12
Fatigue 65 9 35 2 50 8
Arthralgia/myalgia 11 <1 (11–21) (0) 25 0
Decreased appetite 48 2 12 <1 58 4
Vomiting 34 2 (15–17) (0) 39 4
Nausea 54 4 14 <1 62 8
Stomatitis 24 2 2 0 25 2
Hypertension 52 15 Not defined Not defined 48 17
Peripheral edema 9 0 4 0 15 0
Cough 18 <1 9 0 17 2
Abdominal pain 20 4 (11–13) (0) 31 4
Dyspnea 22 3 7 1 21 2
Decreased weight 33 2 Not defined Not defined 48 6
Palmer-plantar erthrodysesthesia 50 8 Not defined Not defined 15 0
Constipation 25 <1 (9–23) (0) 37 0
Pruritus 8 0 14 0 6 0
Rash 15 <1 10 <1 17 0
Choueiri et al. 2015 [54] Motzer et al. 2015 [72]
CheckMate 025 Trial
Motzer et al. 2015 [60, 69, 72]
Common adverse reactions observed in patients with mRCC treated with novel therapies. The incidences reported have been extracted from the clinical trials
leading to each agents FDA approval, respectively. Reported incidence in parentheses were extracted from general drug data, not specific to mRCC and not from
the indicated study
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Patients were stratified in a 1:1:1 ratio and received len-
vatinib, everolimus, or combination therapy with a pri-
mary endpoint of mPFS. Lenvatinib plus everolimus
significantly prolonged mPFS compared to everolimus,
14.6 to 5.5 months, but not to single-agent lenvatinib,
7.4 months. Moreover, OS was increased in the group
receiving the dual-therapy compared to everolimus
alone, although not statistically significant. Single-agent
lenvatinib significantly prolonged mPFS compared to
everolimus as well. However, the size of the benefit of
the combination therapy as compared to the benefit of
single-agent lenvatinib suggests that efficacy was most
robust with the combination therapy [63]. The design of
this three-armed study not only provides objective clin-
ical data but also presents an emerging concept in
mRCC therapy that combination drugs targeting mul-
tiple pathways (in this case VEGF and mTOR) could
simultaneously inhibit two critical independent pathways
synergistically and can potentially prevent resistance to
single-agent therapy [62].
The toxicity profile of the combination therapy was con-
sistent with the known toxicities of each individual agent
(Table 1). Expectedly, the combination therapy exhibited
more frequent adverse events than either single therapy.
These most common grade 3 and 4 treatment-emergent
adverse events from the dual-therapy patient group in-
clude constipation (37%), diarrhea (20%), fatigue (14%),
and hypertension (14%). The increased likelihood of tox-
icity is an appreciable concern and should be considered
by clinicians when deciding upon second-line therapy.
Immunotherapy with PD-1 and PD-L1 inhibitors
mRCC is highly immunogenic. Neoplastic cells evade
immune cell surveillance allowing for uninhibited and
unregulated cell growth. The novel principle underlying
immunotherapy entails the activation of the endogenous
immune system to target cancer at the cellular level and
enable checkpoint inhibition [64]. Immunotherapy
agents at work in mRCC have a role in two-principle im-
mune signaling mechanisms: (1) cytotoxic T-
lymphocyte-associated antigen 4 (CTLA-4) and (2) pro-
grammed death receptor-1 (PD-1). These two receptors
are negative immune regulators imperative to preventing
autoimmunity and are endogenous signals for suppres-
sion of lymphocytes and natural killer (NK) cells. Al-
though the ability of cancer cells to suppress the
immune system is maladaptive, researchers have been
able to use this facet of cancer biology as a target for
drug development [65].
The targeted therapies reviewed above and immuno-
therapies have vastly different mechanisms of action; how-
ever, both treatment modalities show durable responses in
mRCC tumor regression. Interestingly, studies have shown
that targeted therapies are able to dramatically enhance
immune cell function as well. Together, this creates a
paradigm whereby immunotherapy and targeted therapy
can be employed concomitantly with a synergistic effect
[66]. Herein, we describe the immunotherapies approved
by the FDA for mRCC including the newly approved
agent nivolumab and highlight the promising data that led
to nivolumab’s approval.
PD-1 is a cell surface glycoprotein expressed on T-
lymphocytes, B-lymphocytes, macrophages, and NK cells.
Ligand binding of the PD-1 receptor inhibits the effector
phase of T cell activation and thereby serves as a potent
immune checkpoint receptor [6]. The pathogenesis of
mRCC cells and their immunomodulatory effect stems
from the interface between malignant cells and the PD-1
receptor. The natural ligand to PD-1 is the PD-1 ligand
(PD-L1), which is expressed on antigen-presenting cells.
Importantly, populations of mRCC cells have also been
shown to express PD-L1, and this mimicry can result in
not only unregulated tumor cell growth but also apoptosis
of antigen-specific T cells [11, 67]. This interplay between
malignant cells and immune cells creates a tumor micro-
environment with an active yet functionally impaired im-
mune system. Studies have gone on to show that the
degree of PD-L1 expression on mRCC cells directly corre-
lates with aggressive pathologic features including ad-
vanced TNM staging, tumor size, higher nuclear grade,
coagulative necrosis, increased disease progression, cancer-
specific death, and overall mortality [68].
Nivolumab is a fully humanized immunoglobulin G4
PD-1 immune checkpoint inhibitor antibody that select-
ively blocks the receptor activation of PD-L1 and PD-L2.
Ultimately, nivolumab enhances T cell function which
results in antitumor activity [69]. Nivolumab has chan-
ged the landscape for multiple solid and liquid tumors
and currently holds FDA approval for the treatment of
melanoma, squamous non-small cell lung cancer, and
classical Hodgkin’s lymphoma as well as mRCC. The
CheckMate016 phase I trial included patients with
mRCC and was first presented at ASCO 2015. This
study demonstrated that a combination of nivolumab
and ipilimumab exhibited a durable antitumor effect
with a manageable safety profile [70]. A recently re-
ported 5-year follow-up investigation of the phase I par-
ticipants revealed a 34% 5-year survival rate for mRCC
patients whom failed prior anti-angiogenesis therapy and
then placed on maintenance nivolumab [71].
Building on these promising results, investigators re-
cruited 168 patients with histological confirmation of
mRCC for a phase II study. The patient had received prior
treatment with either a VEGF TKI or VEGF monoclonal
antibody and suffered from progression of disease. Pa-
tients were stratified to receive varying doses of nivolumab
as a single-agent therapy. The study successfully demon-
strated nivolumab to prolong mPFS (2.7–4.7 months),
Zarrabi et al. Journal of Hematology & Oncology  (2017) 10:38 Page 6 of 12
ORR (20–22%), and mOS (18.2–25.5). Together, the re-
sults of the study suggested promising antitumor activity
while exhibiting minimal systemic toxicities [69].
The abovementioned results were encouraging as a
proof-of-principle validating immunotherapy as a treat-
ment option for mRCC. CheckMate 025 trial was the first
phase III randomized controlled trial examining nivolu-
mab in advanced RCC. Nivolumab was compared to
everolimus in disease refractory to VEGFR targeted ther-
apy. Eight hundred twenty-one patients were stratified to
receive either nivolumab or everolimus with a primary
endpoint of OS. Secondary endpoints included ORR and
safety. The results from this study were remarkable and
ultimately led to FDA approval of the drug. mOS was 25.0
versus 19.6 months for nivolumab and everolimus, re-
spectively, and met the predetermined criteria for signifi-
cance. The hazard ratio (HR) for nivolumab met
superiority over everolimus (HR 0.73, p < 0.0148). Further
significant findings indicating nivolumab superiority in-
cluded an ORR of 25 versus 5% and an OR of 5.98. There
was no difference in mPFS between the two agents. More-
over, the safety and tolerability profiles favored nivolumab
over everolimus (Table 1). Nineteen percent of the
nivolumab-treated patients reported grade 3 or 4
treatment-related adverse effects compared to 37% of the
patients whom had received everolimus. Of note, the dur-
able responses seen by nivolumab were irrespective of
MSKCC prognostic score, number of previous anti-
angiogenic therapies, and PD-L1 expression [72]. Data ex-
trapolated from the CheckMate 025 trial analyzed the role
of nivolumab treatment after progression, an emerging
concept in clinical oncology [73]. With regard to the pa-
tients in the study treated with nivolumab, 171 of the en-
rolled patients were treated beyond progression of disease.
The patients treated beyond progression experienced a
mOS of 28.1 months compared to 15.0 months for the
group not treated after progression (p < 0.001) [74]. These
data are suggestive that the immune response of nivolu-
mab may be delayed, and further studies are necessary to
fully elucidate the timing of the clinical effect of the drug.
A 2016 study building off the results from the Check-
Mate 025 trial compared health-related quality of life
(HRQoL) for patients in the treatment groups of this
trial. Nivolumab was associated with an improved
HRQoL compared to everolimus in this study popula-
tion [75]. Although there was no significant difference in
the mPFS observed, ad hoc sensitivity analysis of mPFS
in the patients whom had not progressed or died within
six months of treatment revealed a delay in progression
on nivolumab that achieved statistical significance. The
landmark CheckMate 025 trial and subsequent studies
have resulted in labeling nivolumab as the leading
monotherapy for second-line therapy for those who fail
VEGFR-targeting therapies [76].
More recent studies have shown that the immunomod-
ulatory effect of nivolumab in the mRCC tumor micro-
environment is expansive [77]. In an elegantly designed
study, baseline and on-treatment biopsies were obtained
from mRCC patients receiving nivolumab therapy (both
treatment-naïve and refractory disease patients). Immuno-
histochemical analysis of these biopsies demonstrated an
increased lymphocytic presence in the nivolumab-treated
group, reversal of T cell exhaustion within the tumor
microenvironment, upregulation of genes that are hall-
marks of the Th1 inflammatory response, and increased
tumor trafficking or infiltration of T cells. The investiga-
tors also report an increase in expression of genes linked
to NK cells, suggesting that the immunomodulatory effect
of nivolumab may be augmented with NK cell-directed
therapies in the future [78].
Treatment selection after anti-angiogenesis
therapy
The optimal sequencing of mRCC treatment beyond first-
line VEGF TKIs remains controversial, as there are no
head-to-head comparisons between currently approved
drugs. Everolimus was the first drug approved for second-
line treatment of mRCC based on mPFS benefit over pla-
cebo; however, objective tumor response was low, and no
overall survival benefit had been demonstrated [48]. Nivo-
lumab is arguably the most promising agent with a unique
immune mechanism of action and showing an OS benefit
over everolimus in the second-line treatment of mRCC. In
contrast to previously held belief, there was no significant
difference in the median time to progression for nivolu-
mab versus everolimus [72]. Lenvatinib in combination
with everolimus, in a phase II trial, demonstrated to offer
mPFS benefit over single-agent everolimus, but not over
single-agent lenvatinib. Further studies are needed to de-
fine the role of lenvatinib, and the cost of combination
therapy may be an issue to consider in clinical practice.
The OS benefit of both these agents over everolimus is re-
markable and solidifies both agents as marked improve-
ments over the therapies previously available for use in
clinical practice.
Among TKIs currently approved for second-line use, only
axitinib and sorafenib have been compared in a head-to-
head fashion. Axitinib is more potent and selective than so-
rafenib. In the AXIS trial, it demonstrated mPFS benefit
over sorafenib, but no overall survival benefit [55]. Cabo-
zantinib has the theoretical benefit of additional inhibition
of MET and AXL, which are believed to play a role in the
resistance of mRCC to VEGF-directed therapy [57]. Cabo-
zantinib remains the only agent with OS, mPFS, and ORR
benefit over everolimus [38]. At the moment, cabozantinib
is the preferred TKI in our opinion; however, argument can
be made for reserving its use for progression of disease, as
cabozantinib was shown to be effective in METEOR trial
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for patients previously treated with more than one line of
VEGF TKIs.
The approach to the decision of drug sequence re-
quires consideration of the drug’s side-effect profile and
patient preference. Nivolumab is a biweekly intravenous
infusion while cabozantinib is an oral medication that is
more convenient but subject to patient compliance. The
most common side effect of nivolumab appears to be fa-
tigue, while cabozantinib causes more diarrhea and
hand-foot syndrome.
There is no level 1 data to guide the choice between
nivolumab and cabozantinib, and the argument can be
made in favor of either. A recent study compared the ef-
ficacy of nivolumab and cabozantinib through the ana-
lysis of data from multiple trials. By extracting survival
data from original study data and analyzing the hazard
ratio over time, the authors found that the hazard ratio
for OS favors cabozantinib in the first few months but
then nivolumab afterwards [79]. A conclusion may be
drawn that patients with poor prognosis benefit more
from cabozantinib while patients with a better prognosis
will benefit more from nivolumab. This conclusion is
supplemented by the latest update from the METEOR
trial, which provides direct evidence supporting the use
of cabozantinib in high-risk patients [38]. On the other
hand, data from the subgroup analysis of CheckMate
025 trial suggests nivolumab is of benefit across sub-
groups including high-risk patients.
We have learned from the INTORSECT trial that sorafe-
nib offers superior OS over temsirolimus in the second-line
setting and that continued VEGF-directed therapy beyond
first-line sunitinib is more efficacious than mTOR inhibitor
[43]. In the following years, the large multicenter AXIS,
CheckMate, METEOR, and INTORSECT trials introduced
a multitude of new promising agents (Table 2). Though
these studies have established a role for novel therapies,
there is a degree of disconnect between the individual stud-
ies and the overall treatment landscape for mRCC.
In our opinion, we recommend choosing either cabozan-
tinib or nivolumab for patients with mRCC who progressed
on first-line VEGFR-directed therapy, with cabozantinib
preference for patients with high volume disease or symp-
toms due to its PFS benefit (Fig. 1). Both are acceptable op-
tions despite no current level 1 data to support the use of
one agent over the other. Lenvatinib with everolimus, too,
is a viable option in this setting with its appeal being dual
therapy and multiple targets. Drug adverse effects and pa-
tient preference consideration should play the deciding role.
In practice, we suggest substituting to the alternative agent
upon progression of disease before considering everolimus,
as both are superior to everolimus in OS. Given the data
from the INTORSECT trial, we would consider the use of
alternative VEGFR TKIs, e.g., axitinib and sorafenib, prior
to the use of everolimus. This recommendation is offered
with the caveat that neither has been directly compared to
everolimus. Lastly, clinical trial participation is always en-
couraged during any stage of treatment. The Check-
Mate214 trial is an ongoing phase II trial comparing
nivolumab and ipilimumab versus sunitinib in the first-line
setting [80] (Table 3). Such trials assessing immunother-
apies are most promising to fully elucidate the survival
benefit immunotherapies will have compared to the TKI
and monoclonal antibody class agents.
Conclusions
Long-term control of disease in the treatment of mRCC
has been a challenge due to drug resistance. We have
witnessed the armamentarium of treatment options for
mRCC rapidly evolve, including the approval of the
novel agents cabozantinib, nivolumab, and lenvatinib.
mPFS and OS have been prolonged, toxicities reduced,
and treatment options have been extended to the third-
and fourth-line settings with the design of targeted and
immunotherapies. Additionally, a number of active clin-
ical trials are examining agents for future use in mRCC
and will further expand the list of FDA-approved drugs
(Table 3). However, the tremendous rate by which novel
agents are being designed has created a level of com-
plexity which clinicians must manage; treatment plans
for patients have become highly variable with fewer
studies assessing optimal sequence or combination of
agents [64]. The question of sequencing is not unique to
mRCC, as this dilemma is commonly faced when mul-
tiple therapeutic agents are developed over a short
period of time for any disease process [44]. Thankfully,
there are a number of randomized phase II and III trials
currently ongoing that are examining both sequencing
and combinatorial effects of already employed agents.
Future directions for the management of mRCC are not
limited to studies investigating optimal sequence of therap-
ies. There remains ambiguity as to the response of different
histological subtypes of RCC to standard treatments [47].
There have been a number of studies in this area; however,
the complexity of the various molecular mechanisms be-
hind each subtype requires more expansive research efforts.
Histological and pathological variants differ in disease biol-
ogy, clinical behavior, prognosis, and response to systemic
therapy [81]. Characterizing the molecular basis for each
subtype will allow for greater precision for future clinical
trial design with regard to targeted therapy and choice of
agents. Active clinical trials are investigating possible syner-
gism between concomitant targeted therapy and immuno-
therapy (Table 3). The potential of these studies, together
with the advances in genomic medicine, provides a promis-
ing outlook for future care of patients with RCC.
In this review, we have highlighted the current land-
scape for mRCC treatment in the first-line and second-
line settings. The anti-angiogenesis agents, sunitinib and
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pazaopanib, have remained the most utilized first-line
agents [82]. After the use of these agents, axitinib and
everolimus have been used extensively, but now, new
agents including cabozantinib, nivolumab, and lenvatinib
in combination with everolimus have provided a para-
digm shift for the treatment of patients with prior anti-
angiogenesis therapy. These novel therapies have gained
traction for use in the second-line setting since their
Table 2 Major clinical trials for the treatment of mRCC after anti-angiogenesis therapy
Study Everolimus Axitinib Sorafenib Cabozantinib Nivolumab Lenvatinib/
everolimus
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Italics indicate statistical significance in data findings
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Fig. 1 Suggested approach to treatment after anti-angiogenesis therapy. Suggested algorithm for treatment options for mRCC. Sunitnib and
pazopanib are recommended in the first-line setting, with the exception of selected patients who may benefit from temsirolimus or IL-2. Upon
disease progression, second-line agents can be chosen at the discretion of the clinician. The algorithm provided is based on current clinical data
and practice guidelines
Table 3 Active clinical trials investigating future immunotherapies in mRCC
Trial Phase Estimated completion Disease setting Standard treatment Experimental treatment
NCT01582672 III April 2017 Advanced renal cell carcinoma Sunitinib Sunitinib + AGS-003






NCT02917772 II April 2018 Advanced renal cell carcinoma None Nivolumab + ipilimumab





None Nivolumab + HBI-8000
NCT02853331 III December 2019 Metastatic ccRCC Sunitinib Pembrolizumab + axitinib
NCT02684006 III June 2018 Metastatic ccRCC Sunitinib Avelumab + axitinib
NCT02231749 III June 2019 Advanced renal cell carcinoma Sunitinib Nivolumab + ipilimumab
NCT02420821 III July 2020 Advanced renal cell carcinoma Sunitinib Bevacizumab + atezolizumab
NCT02811861 III October 2019 Metastatic ccRCC Sunitinib Lenvatinib + everolimus
OR
Lenvatinib + pembrolizumab
Active trials investigating the roles of various immunotherapies in advanced and metastatic RCC. All trial information obtained through publicly accessible
clinicaltrials.gov. AGS-003 is an autologous dendritic cell immunotherapy. ImmuniCell® is an autologous γδ T-lymphocyte immunotherapy. HBI-8000 (Chidamide) is
a novel oral histone deacetylase inhibitor and epigenetic modulator
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FDA approval. Questions remain as to what is the
optimal selection of drugs in this setting. The combin-
ation of novel immunotherapies with targeted therapy
has potential to dramatically improve the outcome for
patients with mRCC.
Abbreviations
ccRCC: Clear cell renal cell carcinoma; CTLA-4: Cytotoxic T-lymphocyte-
associated antigen 4; HRQoL: Health-related quality of life; IFN-α: Interferon-
alpha; IL-2: Interleukin-2; mOS: Median overall survival; mPFS: Median
progression-free survival; mRCC: Metastatic renal cell carcinoma;
mTOR: Mammalian target of rapamycin; NCCN: National Comprehensive
Cancer Network; nccRCC: Non-clear cell renal cell carcinoma; NK: Natural
killer; ORR: Objective response rate; OS: Overall survival; PD-1: Programmed
death receptor-1; PD-1L: PD-1 ligand; PDGF: Platelet-derived growth factor;
PFS: Progression-free survival; RCC: Renal cell carcinoma; TKI: Tyrosine kinase
inhibitor; VEGF: Vascular endothelial growth factor; VEGFR: Vascular




This report required no funding.
Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated
or analyzed during the current study.
Authors’ contributions
KZ, CF, and SW contributed to the writing of the manuscript and creating of
the table. All authors read and approved the final manuscript.
Competing interests




Ethics approval and consent to participate
Not applicable.
Received: 3 November 2016 Accepted: 8 December 2016
References
1. Vitale{Vitale MG, Carteni G. Recent developments in second and third line
therapy of metastatic renal cell carcinoma. Expert Rev Anticancer Ther.
2016;16(5):469-71.
2. Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387(10021):894–906.
3. Coppin C, et al. Immunotherapy for advanced renal cell cancer. Cochrane
Database Syst Rev. 2005;1:CD001425.
4. Ravaud A, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after
nephrectomy. N Engl J Med. 2016.
5. Kabaria R, Klaassen Z, Terris MK. Renal cell carcinoma: links and risks.
Int J Nephrol Renovasc Dis. 2016;9:45–52.
6. Xu KY, Wu S. Update on the treatment of metastatic clear cell and non-clear
cell renal cell carcinoma. Biomark Res. 2015;3:5.
7. Srinivasan R, et al. New strategies in renal cell carcinoma: targeting the
genetic and metabolic basis of disease. Clin Cancer Res. 2015;21(1):10–7.
8. Latif F, et al. Identification of the von Hippel-Lindau disease tumor
suppressor gene. Science. 1993;260(5112):1317–20.
9. Nickerson ML, et al. Improved identification of von Hippel-Lindau gene
alterations in clear cell renal tumors. Clin Cancer Res. 2008;14(15):4726–34.
10. Fyfe G, et al. Results of treatment of 255 patients with metastatic renal cell
carcinoma who received high-dose recombinant interleukin-2 therapy.
J Clin Oncol. 1995;13(3):688–96.
11. Koshkin VS, Rini BI. Emerging therapeutics in refractory renal cell carcinoma.
Expert Opin Pharmacother. 2016;17(9):1225–32.
12. Negrier S, et al. Long-term follow-up of patients with metastatic renal cell
carcinoma treated with intravenous recombinant interleukin-2 in Europe.
Cancer J Sci Am. 2000;6 Suppl 1:S93–8.
13. NCCN Clinical Practice Guidelines in Oncology. [Webpage] 2016 2016];
Available from: https://www.nccn.org/professionals/physician_gls/f_
guidelines.asp. Accessed 9 Jan 2016.
14. Ljungberg B, et al. EAU guidelines on renal cell carcinoma: 2014 update.
Eur Urol. 2015;67(5):913–24.
15. Motzer RJ, et al. Sunitinib in patients with metastatic renal cell carcinoma.
JAMA. 2006;295(21):2516–24.
16. Motzer RJ, et al. Overall survival and updated results for sunitinib compared
with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol.
2009;27(22):3584–90.
17. Sternberg CN, et al. Pazopanib in locally advanced or metastatic renal cell
carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8.
18. Sternberg CN, et al. A randomised, double-blind phase III study of
pazopanib in patients with advanced and/or metastatic renal cell
carcinoma: final overall survival results and safety update. Eur J Cancer.
2013;49(6):1287–96.
19. Motzer RJ, et al. Pazopanib versus sunitinib in metastatic renal-cell
carcinoma. N Engl J Med. 2013;369(8):722–31.
20. Trump, D. Commentary on: “Randomized, controlled, double-blind, cross-
over trial assessing treatment preference for pazopanib versus sunitinib in
patients with metastatic renal cell carcinoma: PISCES study.” Escudier B,
Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U,
Parikh O, Hawkins R, Sevin E, Negrier S, Khan S, Diaz J, Redhu S, Mehmud F,
Cella D. Bernard Escudier, Institut Gustave Roussy, Villejuif; Emmanuel Sevin,
Centre Francois Baclesse, Caen; Sylvie Negrier, Leon Berard Cancer Center,
Lyon, France; Camillo Porta, Fondazione Istituto di Ricovero e Cura a
Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia; Cora N Sternberg,
San Camillo Forlanini Hospital, Rome; Ugo De Giorgi, IRCCS Istituto
Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy;
Petri Bono, Helsinki University Central Hospital, Helsinki, Finland; Thomas
Powles, Barts Experimental Cancer Medicine Centre, Barts Cancer Institute,
Queen Mary University of London, London; Tim Eisen, Cambridge University
Health Partners, Cambridge; Omi Parikh, Royal Preston Hospital, Lancashire;
Robert Hawkins, Christie Cancer Research UK, Manchester; Sadya Khan, Jose
Diaz, and Faisal Mehmud, GlaxoSmithKline, Uxbridge, United Kingdom;
Jurgen E Gschwend, Klinikum Rechts der Isar der Technischen Universitat
Munchen, Munich, Germany; Suman Redhu, GlaxoSmithKline, Collegeville,
PA; David Cella, Northwestern University Feinberg School of Medicine,
Chicago, IL.: J Clin Oncol. 2014 May 10;32(14):1412-1418; doi: 10.1200/JCO.
2013.50.8267. [Epub 2014 Mar 31]. Urol Oncol. 2016;34(5):251.
21. Gupta S, Spiess PE. The prospects of pazopanib in advanced renal cell
carcinoma. Ther Adv Urol. 2013;5(5):223–32.
22. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma.
Clin Cancer Res. 2004;10(18 Pt 2):6388S–92S.
23. Escudier B, et al. Sorafenib in advanced clear-cell renal-cell carcinoma.
N Engl J Med. 2007;356(2):125–34.
24. Escudier B, et al. Sorafenib for treatment of renal cell carcinoma: final
efficacy and safety results of the phase III treatment approaches in renal
cancer global evaluation trial. J Clin Oncol. 2009;27(20):3312–8.
25. Escudier B, et al. Randomized phase II trial of first-line treatment with
sorafenib versus interferon Alfa-2a in patients with metastatic renal cell
carcinoma. J Clin Oncol. 2009;27(8):1280–9.
26. Hutson TE, et al. Axitinib versus sorafenib as first-line therapy in patients
with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Lancet Oncol. 2013;14(13):1287–94.
27. Choueiri TK. CABOzantinib versus SUNitinib (CABOSUN) as initial targeted
therapy for patients with metastatic renal cell carcinoma (mRCC) of poor
and intermediate risk groups: results from ALLIANCE A031203 trial, in ESMO
2016 Congress. Copenhagen; 2016.
28. Agostino NM, Gingrich R, Drabick JJ. Bevacizumab demonstrates prolonged
disease stabilization in patients with heavily pretreated metastatic renal cell
carcinoma: a case series and review of the literature. Adv Urol. 2010.
29. Yang JC, et al. A randomized trial of bevacizumab, an anti-vascular
endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med.
2003;349(5):427–34.
30. Escudier B, et al. Bevacizumab plus interferon alfa-2a for treatment of
metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Lancet. 2007;370(9605):2103–11.
Zarrabi et al. Journal of Hematology & Oncology  (2017) 10:38 Page 11 of 12
31. Escudier B, et al. Phase III trial of bevacizumab plus interferon alfa-2a in
patients with metastatic renal cell carcinoma (AVOREN): final analysis of
overall survival. J Clin Oncol. 2010;28(13):2144–50.
32. Rini BI, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon
alfa monotherapy in patients with metastatic renal cell carcinoma: final results
of CALGB 90206. J Clin Oncol. 2010;28(13):2137–43.
33. Sawyers CL. Will mTOR inhibitors make it as cancer drugs? Cancer Cell.
2003;4(5):343–8.
34. Yuan R, et al. Targeting tumorigenesis: development and use of mTOR inhibitors
in cancer therapy. J Hematol Oncol. 2009;2:45.
35. Akinleye A, et al. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer
therapeutics. J Hematol Oncol. 2013;6(1):88.
36. Albanell J, et al. mTOR signalling in human cancer. Clin Transl Oncol.
2007;9(8):484–93.
37. Brugarolas J. Renal-cell carcinoma—molecular pathways and therapies.
N Engl J Med. 2007;356(2):185–7.
38. Choueiri TK, et al. Cabozantinib versus everolimus in advanced renal cell
carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Lancet Oncol. 2016;17(7):917–27.
39. Voss MH, Molina AM, Motzer RJ. mTOR inhibitors in advanced renal cell
carcinoma. Hematol Oncol Clin North Am. 2011;25(4):835–52.
40. Ge N, et al. Impact of O6-methylguanine-DNA methyltransferase expression
on the drug resistance of clear cell renal cell carcinoma. Jpn J Clin Oncol.
2015;45(9):860–6.
41. Rini BI, et al. Comparative effectiveness of axitinib versus sorafenib in
advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet.
2011;378(9807):1931–9.
42. Buti S, et al. Chemotherapy in metastatic renal cell carcinoma today?
A systematic review. Anticancer Drugs. 2013;24(6):535–54.
43. Burris 3rd HA. Overcoming acquired resistance to anticancer therapy:
focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol.
2013;71(4):829–42.
44. Fischer S, Gillessen S, Rothermundt C. Sequence of treatment in locally
advanced and metastatic renal cell carcinoma. Transl Androl Urol.
2015;4(3):310–25.
45. Motzer RJ, et al. Efficacy of everolimus in advanced renal cell carcinoma:
a double-blind, randomised, placebo-controlled phase III trial. Lancet.
2008;372(9637):449–56.
46. Motzer RJ, et al. Phase II trial of second-line everolimus in patients with
metastatic renal cell carcinoma (RECORD-4). Ann Oncol. 2016;27(3):441–8.
47. Armstrong AJ, et al. Everolimus versus sunitinib for patients with metastatic
non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label,
randomised phase 2 trial. Lancet Oncol. 2016;17(3):378–88.
48. Hutson TE, et al. Randomized phase III trial of temsirolimus versus sorafenib
as second-line therapy after sunitinib in patients with metastatic renal cell
carcinoma. J Clin Oncol. 2014;32(8):760–7.
49. Escudier B, Gore M. Axitinib for the management of metastatic renal cell
carcinoma. Drugs R D. 2011;11(2):113–26.
50. Motzer RJ, et al. Axitinib versus sorafenib as second-line treatment for
advanced renal cell carcinoma: overall survival analysis and updated results
from a randomised phase 3 trial. Lancet Oncol. 2013;14(6):552–62.
51. Vitale MG, Carteni G. Recent developments in second and third line therapy
of metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2016;16(5):
469–71.
52. Zhou L, et al. Targeting MET and AXL overcomes resistance to sunitinib
therapy in renal cell carcinoma. Oncogene. 2016;35(21):2687–97.
53. Rankin EB, et al. Direct regulation of GAS6/AXL signaling by HIF promotes
renal metastasis through SRC and MET. Proc Natl Acad Sci U S A. 2014;
111(37):13373–8.
54. Choueiri TK, et al. Cabozantinib versus everolimus in advanced renal-cell
carcinoma. N Engl J Med. 2015;373(19):1814–23.
55. Escudier B, et al. Axitinib versus sorafenib in advanced renal cell carcinoma:
subanalyses by prior therapy from a randomised phase III trial. Br J Cancer.
2014;110(12):2821–8.
56. Matsui J, et al. E7080, a novel inhibitor that targets multiple kinases, has
potent antitumor activities against stem cell factor producing human small
cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer.
2008;122(3):664–71.
57. Boss DS, et al. A phase I study of E7080, a multitargeted tyrosine kinase
inhibitor, in patients with advanced solid tumours. Br J Cancer. 2012;106(10):
1598–604.
58. Schlumberger M, et al. A phase II trial of the multitargeted tyrosine kinase
inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clin Cancer Res.
2016;22(1):44–53.
59. Sonpavde G, Willey CD, Sudarshan S. Fibroblast growth factor receptors as
therapeutic targets in clear-cell renal cell carcinoma. Expert Opin Investig
Drugs. 2014;23(3):305–15.
60. Motzer RJ, et al. Lenvatinib, everolimus, and the combination in patients
with metastatic renal cell carcinoma: a randomised, phase 2, open-label,
multicentre trial. Lancet Oncol. 2015;16(15):1473–82.
61. Fabian MA, et al. A small molecule-kinase interaction map for clinical kinase
inhibitors. Nat Biotechnol. 2005;23(3):329–36.
62. Sosman JA, Puzanov I, Atkins MB. Opportunities and obstacles to
combination targeted therapy in renal cell cancer. Clin Cancer Res. 2007;
13(2 Pt 2):764s–9s.
63. Molina AM, et al. A phase 1b clinical trial of the multi-targeted tyrosine
kinase inhibitor lenvatinib (E7080) in combination with everolimus for
treatment of metastatic renal cell carcinoma (RCC). Cancer Chemother
Pharmacol. 2014;73(1):181–9.
64. Atkins MB, Larkin J. Immunotherapy combined or sequenced with targeted
therapy in the treatment of solid tumors: current perspectives. J Natl Cancer Inst.
2016;108(6):djv414.
65. Ma W, et al. Current status and perspectives in translational biomarker
research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol.
2016;9(1):47.
66. Kadowaki N. Combination of targeted therapy and immunotherapy for
cancer. Gan To Kagaku Ryoho. 2015;42(9):1046–9.
67. Dong H, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a
potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.
68. Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear
cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res.
2007;13(2 Pt 2):709s–15s.
69. Motzer RJ, et al. Nivolumab for metastatic renal cell carcinoma: results of a
randomized phase II trial. J Clin Oncol. 2015;33(13):1430–7.
70. Cancer MRC. Summary from ASCO 2015. Can Urol Assoc J. 2015;9(7-8):S158–61.
71. McDermott DF. Long-term overall survival (OS) with nivolumab in
previously treated patients with advanced renal cell carcinoma (aRCC) from
phase I and II studies. In 2016 ASCO Annual Meeting. 2016.
72. Motzer RJ, et al. Nivolumab versus everolimus in advanced renal-cell
carcinoma. N Engl J Med. 2015;373(19):1803–13.
73. Yerushalmi R, Gelmon K. Treatment beyond progression: is it moving from
belief to evidence? Oncologist. 2010;15(8):796–8.
74. George S, et al. Safety and efficacy of nivolumab in patients with metastatic
renal cell carcinoma treated beyond progression: a subgroup analysis of a
randomized clinical trial. JAMA Oncol. 2016;2(9):1179–86.
75. Cella D, et al. Quality of life in patients with advanced renal cell carcinoma
given nivolumab versus everolimus in CheckMate 025: a randomised, open-
label, phase 3 trial. Lancet Oncol. 2016;17(7):994–1003.
76. Chedgy EC, Black PC. Nivolumab: the new second line treatment for
advanced renal-cell carcinoma commentary on: nivolumab versus
everolimus in advanced renal-cell carcinoma. Urology. 2016;89:8–9.
77. Choueiri TK, et al. Immunomodulatory activity of nivolumab in metastatic
renal cell carcinoma. Clin Cancer Res, 2016.
78. Das R, et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to
distinct immunologic changes in vivo. J Immunol. 2015;194(3):950–9.
79. Wiecek W, Karcher H. Nivolumab versus cabozantinib: comparing overall
survival in metastatic renal cell carcinoma. PLoS One. 2016;11(6):e0155389.
80. Rexer H. Therapy of untreated local advanced or metastatic renal cell
carcinoma. Phase III, randomized, open-label study of nivolumab combined
with ipilimumab versus sunitinib monotherapy in subjects with previously
untreated, local advanced or metastatic renal cell carcinoma (CheckMate
214 - AN 36/15 of the AUO). Urologe A. 2015;54(10):1443–5.
81. Shuch B, et al. Understanding pathologic variants of renal cell carcinoma:
distilling therapeutic opportunities from biologic complexity. Eur Urol.
2015;67(1):85–97.
82. Hackshaw MD, et al. Prescribing preferences in the first-line treatment for
patients with metastatic renal cell carcinoma in the United States.
Clin Genitourin Cancer, 2016.
Zarrabi et al. Journal of Hematology & Oncology  (2017) 10:38 Page 12 of 12
